LQDA News and Press, Liquidia Technologies Inc. From 03/03/24

2024-03-03 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-15 11:35:43 ET Summary Liquidia Corporation shares rallied over 80% after an appeals court invalidated the patent of rival United Therapeutics, potentially paving the way for approval of its PAH and PH-ILD medication Yutrepia. However, the FDA recently extended the origina...

2024-02-14 19:49:34 ET Summary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing form...

2024-02-12 22:49:38 ET Summary Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a s...

2024-01-31 07:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 throu...

2024-01-25 08:25:44 ET More on Pre-market losers & stocks. LG Display Co Ltd (LPL) Q4 2023 Earnings Call Transcript LG Display: It Is The Long-Term Picture That Is Giving People Pause Silo Pharma stock rises after inking exclusive license deal with Medspray Pharm...

2024-01-25 06:48:59 ET More on Liquidia Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia Gains Edge In PAH Market Following Key Legal Victory Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript Liquidia announces updates...

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat...

2024-01-19 15:00:29 ET More on the markets SPY Is At Its Highest Risk Level (Technical Analysis) Recession Forecasting: Indicators That Actually Help Your Portfolio (Part 3) New Secular Bull Markets Hidden In Plain Sight Investors retract capital from the fun...